OncoInfo

    • Home
    • Temi
      • Prevenzione
      • Cure palliative e terapie di supporto
      • Diagnosi
      • Terapia
    • Speciali
      • Medicina di precisione
        • Dai Congressi
        • Materiali
        • Normativa
        • Letteratura
        • Newsletter
      • Politica sanitaria
      • Oncologia pediatrica
    • Congressi
      • 4words
      • AIOM
      • ASCO
        • ASCO
        • ASCO GI
        • ASCO GU
      • BRIDGE
      • ESMO
        • ESMO
        • ESMO GI
      • IMI
      • Internazionali
        • AACR
        • ECC
        • ECCO
        • ELCC
        • IGCS
        • IKCS
        • SABCS
        • SMR
        • WCLC
      • Nazionali
        • CIPOMO
        • CTOS
        • GRANDANGOLO
        • GU
        • NeVento
        • NICSO
        • SIOG
    • Newsletter
    • About
      • Board

    Present and future of immunotherapy in melanoma

      BRIDGE · Congressi · In primo piano · Video
    • 15 Dicembre 2017

    First line choice in melanoma: immunotherapy or target therapy? We asked Omid Hamid, Director of Melanoma Therapeutics of The Angeles Clinic and Research Institute of Santa Monica. And what about monotherapy? In which patients we could use this therapeutical approach? From the Immunotherapy & Melanoma Bridge 2017 held in Naples.


    Potrebbe interessarti anche

    • Immunotherapy: combinations in melanoma

      Michael Postow Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York

    • New frontiers of immunotherapy in non-melanoma skin cancers

      We interviewed Reinhard Dummer and Paolo Ascierto during Immunotherapy Bridge 2018.

    • Pros and cons of sequencing and combinations in Immunotherapy

      Robert L. Ferris Director UPMC Hillman Cancer Center

    • Melanoma treatment: past, present and future...

      Igor Puzanov Roswell Park Comprehensive Cancer Center Jacobs School of Medicine, University at Buffalo

    Tags: 2017Melanoma

    Lascia un commento Annulla risposta

    Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *

    • Dai congressi

      • CAR-T cells therapy in solid tumors: where are we now? 12 Dicembre 2019
      • aCSCC: in arrivo l’immunoterapia con cemiplimab 12 Dicembre 2019
      • aCSCC: with immunotherapy it can be cured 12 Dicembre 2019
      • Ovarian cancer: where are we going with Immunotherapy? 12 Dicembre 2019
      • Host genetic factors as modulators of melanoma immunotherapy outcomes 12 Dicembre 2019
    • Archivio

      • 4words
      • AACR
        • AACR 2016
        • AACR 2018
        • AACR 2019
      • AIOM
        • AIOM 2019
        • AIOM 2018
        • AIOM 2017
        • AIOM 2016
        • AIOM 2015
        • AIOM 2014
        • AIOM 2013
        • AIOM 2012
        • AIOM 2011
      • AIT
      • ASCO
        • ASCO 2019
        • ASCO 2018
        • ASCO 2017
        • ASCO 2016
        • ASCO 2015
        • ASCO 2014
        • ASCO 2013
        • ASCO 2012
        • ASCO 2011
        • ASCO 2010
      • ASCO GI
      • ASCO GU
      • BRIDGE
        • BRIDGE 2018
        • BRIDGE 2017
        • BRIDGE 2016
        • BRIDGE 2015
      • CIOT
      • CIPOMO
      • CTOS
      • ECC
        • ECC 2015
        • ECC 2013
      • ECCO
      • ELCC
      • ESMO
        • ESMO 2019
        • ESMO 2018
        • ESMO 2017
        • ESMO 2016
        • ESMO 2015
        • ESMO 2014
        • ESMO 2012
      • ESMO GI
      • GRANDANGOLO
      • GU
      • IGCS
        • IGCS 2016
      • IKCS
      • IMI
      • NeVento
      • NICSO
      • SABCS
      • SIFO
      • SIOG
      • SIUrO
      • SMR
      • WCLC
    • Redazione

      Editor in Chief: Luciano De Fiore
      Redazione: David Frati, Giulia Volpe, Maria Nardoianni, Livia Costa, Fabio Ambrosino

    • Privacy Policy Cookie Policy
    • ULTIMI ARTICOLI

      • 12 Dicembre 2019  CAR-T cells therapy in solid tumors: where are we now?
      • 12 Dicembre 2019  Speciale IMMUNOTHERAPY & MELANOMA BRIDGE 2019
      • 12 Dicembre 2019  aCSCC: in arrivo l’immunoterapia con cemiplimab
      • 12 Dicembre 2019  aCSCC: with immunotherapy it can be cured
      • 12 Dicembre 2019  Ovarian cancer: where are we going with Immunotherapy?
      • 12 Dicembre 2019  Host genetic factors as modulators of melanoma immunotherapy outcomes
    • ULTIMI VIDEO

      • aCSCC: in arrivo l’immunoterapia con cemiplimab 12 Dicembre 2019
      • aCSCC: with immunotherapy it can be cured 12 Dicembre 2019
      • Ovarian cancer: where are we going with Immunotherapy? 12 Dicembre 2019
      • Host genetic factors as modulators of melanoma immunotherapy outcomes 12 Dicembre 2019
      • Melanoma uveale: una luce dallo studio IMCgp100 28 Novembre 2019
      • laBCC: il nuovo inibitore di Hedgehog 28 Novembre 2019
    • Contatti

      * Campi obbligatori

    Una pubblicazione de Il Pensiero Scientifico Editore | Via San Giovanni Valdarno 8, 00138 Roma | Tutti i diritti riservati | ISSN 2385-0108